Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM
This research study is studying the combination of daratumumab with weekly carfilzomib, pomalidomide, and dexamethasone in people with relapsed and refractory multiple myeloma. Relapsed and Refractory Multiple Myeloma is the condition of returned or previous treatment resistant Multiple Myeloma.

This research study involves two study drugs and two standard of care drugs.

* The names of the study drugs involved in this study are:

  * Carfilzomib
  * Daratumumab
* The names of the standard of care drugs involved in this study are:

  * Dexamethasone
  * Pomalidomide
Multiple Myeloma|Refractory Multiple Myeloma|Multiple Myeloma in Relapse|Relapse
DRUG: Daratumumab|DRUG: Carfilzomib|DRUG: Pomalidomide|DRUG: Dexamethasone
Objective response rate of the daratumumab, carfilzomib, pomalidomide, and dexamethasone combination, Simon's two-stage design will be used. An objective response rate of 40%, 28 Days|Number of dose limiting toxicity grade 4 or higher treatment related, 28 Days
Progression-free survival (PFS), PFS will be estimated using the Kaplan-Meier method, time from randomization to the disease progression or death from any cause up 60 months|Rate of Minimal residual disease (MRD) negative status, Clonal evolution and clonal heterogeneity will be summarized using descriptive statistics, 112 Days
This phase II, multicenter, open-label study is studying daratumumab in combination with weekly carfilzomib, pomalidomide, and dexamethasone in people with relapsed and refractory multiple myeloma who have received at least one prior therapy and who have had previous treatment with both lenalidomide and a proteasome inhibitor.

* The research study procedures include screening for eligibility and study treatment including evaluations and follow up visits. This research study involves two study drugs and two standard of care drugs.
* The names of the study drugs involved in this study are:

  * Carfilzomib
  * Daratumumab
* The names of the standard of care drugs involved in this study are:

  * Dexamethasone
  * Pomalidomide
* A total of 43 participants will be enrolled to this trial
* The U.S. Food and Drug Administration (FDA) has not approved Daratumumab, and Carfilzomib for use in treatment of Multiple Myeloma.